Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly

Health, Fitness & Food

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.
AJ Mast | Bloomberg | Getty Images

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market.

Products You May Like

Articles You May Like

Why Haven’t We Figured Out How to Protect Women Athletes?
Spinach Feta Frittata
I Tested These TikTok-Viral “Breathable” Leggings in a 90-Degree Pilates Class
Healthy Returns: HHS Secretary RFK Jr. is making early moves that may affect vaccine access
Why nursing homes and hospice are so expensive in the U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *